Evidence map›Paper›PMID 41756181›Full record

ArticleJTO clinical and research reports2026

Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma Harboring EML4-NTRK3 Fusion: Case Report.

Vladmir Cláudio Cordeiro de Lima, Breno Jeha Araújo, Felipe D' Almeida Costa, Beatriz Fuga Rossi Teixeira, André Luiz Cicilini, Carolina de Bustamante Fernandes, Juliana Folador Morellato, Rodrigo Dienstmann, Mariana Tosello Laloni

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Vladmir Cláudio Cordeiro de LimaA.C. Camargo Cancer Center, Thoracic Oncology Reference Center, São Paulo, Brazil.
Breno Jeha AraújoOncoclínicas do Brasil, Precision Medicine, São Paulo, Brazil.
Felipe D' Almeida CostaA.C. Camargo Cancer Center, Anatomic Pathology, São Paulo, Brazil.
Beatriz Fuga Rossi TeixeiraA.C. Camargo Cancer Center, Anatomic Pathology, São Paulo, Brazil.
André Luiz CiciliniA.C. Camargo Cancer Center, Department of Medical Oncology, São Paulo, Brazil.
Carolina de Bustamante FernandesOncoclínicas do Brasil, Precision Medicine, São Paulo, Brazil.
Juliana Folador MorellatoA.C. Camargo Cancer Center, Thoracic Oncology Reference Center, São Paulo, Brazil.
Rodrigo DienstmannOncoclínicas do Brasil, Precision Medicine, São Paulo, Brazil.
Mariana Tosello LaloniOncoclínicas do Brasil, Medical Oncology Group, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secretory carcinoma of the lung is an exceptionally rare salivary gland-type malignancy, typically associated with NTRK fusions. We report a 71-year-old woman with pulmonary stage IIIA adenocarcinoma having salivary gland differentiation and solid-cribriform architecture, confirmed by S100 and Pan-TRK immunohistochemistry. Broad DNA and RNA next-generation sequencing identified an

Indexed as

Case reportLarotrectinibNSCLCNTRK fusionSecretory carcinoma

Identifiers

PMID41756181
PMCPMC12933567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.